While a few events, including the US Food and Drug Administration's approval Global Blood Therapeutics Inc.'s sickle cell drug Oxbryta (voxelotor), stole the spotlight in the days leading up to Thanksgiving, sponsors also made a slew of important submission and filing announcements during the short work week.
Genentech Inc. is looking to garner the third FDA approval for a spinal muscular atrophy (SMA) indication after scoring...





